Citations

Clear

904 citation(s) found for "Gordon, S".

Allogeneic transplantation for therapy-related myelodysplastic syndrome and acute myeloid leukemia
Litzow, Mark R. , Tarima, Sergey , Pérez, Waleska S., Bolwell, Brian J., Cairo, Mitchell S. , Camitta, Bruce M., Luger, Selina M. , Marks, David I. , Pasquini, Marcelo C. , Phillips, Gordon L., Rizzo, J. Douglas , Sierra, Jorge , Tallman, Martin S. , Weisdorf, Daniel J. , Cutler, Corey S. , Lima, Marcos de , DiPersio, John F. , Gale, Robert Peter , Keating, Armand , Lazarus, Hillard M. , Maziarz, Richard Thomas , McCarthy, Philip L. , Weisdorf, Dan

Mayo Clinic

Blood | December 24, 2009 | Volume: 115 | Issue: 9 | Pages: 1850-1857

10.1182/blood-2009-10-249128 | PMID 20032503 Get It

Abstract Therapy-related myelodysplastic syndromes (t-MDSs) and acute myeloid leukemia (t-AML) have a poor prognosis with conventional therapy. Encouraging results are reported after allogeneic transplantation. We analyzed outcomes in 868 persons with t-AML (n = 545) or t-MDS (n = 323) receiving allogeneic transplants from 1990 to 2004. A myeloablative regimen was used for conditioning in 77%. Treatment-related mortality (TRM) and relapse were 41% (95% confidence interval [CI], 38-44) and 27% (24-30) at 1 year and 48% (44-51) and 31% (28-34) at 5 years, respectively. Disease-free (DFS) and overall survival (OS) were 32% (95% CI, 29-36) and 37% (34-41) at 1 year and 21% (18-24) and 22% (19-26) at 5 years, respectively. In multivariate analysis, 4 risk factors had adverse impacts on DFS and OS: (1) age older than 35 years; (2) poor-risk cytogenetics; (3) t-AML not in remission or advanced t-MDS; and (4) donor other than an HLA-identical sibling or a partially or well-matched unrelated donor. Five-year survival for subjects with none, 1, 2, 3, or 4 of these risk factors was 50% (95% CI, 38-61), 26% (20-31), 21% (16-26), 10% (5-15), and 4% (0-16), respectively (P < .001). These data permit a more precise prediction of outcome and identify subjects most likely to benefit from allogeneic transplantation.
T-cell acute lymphoblastic leukemia in adults: clinical features, immunophenotype, cytogenetics, and outcome from the large randomized prospective trial (UKALL XII/ECOG 2993)
Marks, David I. , Paietta, Elisabeth , Moorman, Anthony V. , Richards, Susan , Buck, Georgina , Dewald, Gordon W., Ferrando, Adolfo A. , Goldstone, Anthony H., Ketterling, Rhett P. , Litzow, Mark R. , Luger, Selina M. , McMillan, Andrew , Mansour, Marc R. , Rowe, Jacob M. , Tallman, Martin S. , Fielding, Adele K. , Lazarus, Hillard M. , Ketterling, Rhett P

Mayo Clinic

Blood | October 15, 2009 | Volume: 114 | Issue: 25 | Pages: 5136-5145

10.1182/blood-2009-08-231217 | PMID 19828704 Get It

AbstractThe biology and outcome of adult T-cell acute lymphoblastic leukemia are poorly understood. We present here the clinical and biologic features of 356 patients treated uniformly on the prospective trial (UKALL XII/ECOG 2993) with the aim of describing the outcome and identifying prognostic factors. Complete remission was obtained in 94% of patients, and 48% survived 5 years. Positivity of blasts for CD1a and lack of expression of CD13 were associated with better survival (P = .01 and < .001, respectively). NOTCH1 and CDKN2A mutations were seen in 61% and 42% of those tested. Complex cytogenetic abnormalities were associated with poorer survival (19% vs 51% at 5 years, P = .006). Central nervous system involvement at diagnosis did not affect survival (47% vs 48%, P = not significant). For 99 patients randomized between autograft and chemotherapy, 5-year survival was 51% in each arm. Patients with a matched sibling donor had superior 5-year survival to those without donors (61% vs 46%, χ2, P = .02); this was the result of less relapse (25% vs 51% at 5 years, P < .001). Only 8 of 123 relapsed patients survive. This study provides a baseline for trials of new drugs, such as nelarabine, and may allow risk-adapted therapy in patients with poor-prognosis T-cell ALL.
Consensus Recommendations to Accelerate Clinical Trials for Neurofibromatosis Type 2
Evans, D. Gareth , Kalamarides, Michel , Hunter‐Schaedle, Kim, Allen, Jeffrey C. , Babovic-Vuskanovic, Dusica, Belzberg, Allan J. , Bollag, Gideon , Chen, Ruihong , DiTomaso, Emmanuelle, Golfinos, John G. , Harris, Gordon J. , Jacob, Abraham, Kalpana, Ganjam V. , Karajannis, Matthias A. , Korf, Bruce R. , Law, Meng , McClatchey, Andrea I. , Packer, Roger J. , Roehm, Pamela C. , Rubenstein, Allan E., Slattery, William H. , Tonsgard, James H. , Widemann, Brigitte C. , Yohay, Kaleb , Giovannini, Marco , Blakeley, Jaishri O. , Kurzrock, Razelle , Welling, D. Bradley , Evans, D Gareth , Karajannis, Matthias A

Mayo Clinic

Clinical Cancer Research | August 12, 2009 | Volume: 15 | Issue: 16 | Pages: 5032-5039

10.1158/1078-0432.ccr-08-3011 | PMID 19671848 Get It

Abstract Purpose: Neurofibromatosis type 2 (NF2) is a rare autosomal dominant disorder associated primarily with bilateral schwannomas seen on the superior vestibular branches of the eighth cranial nerves. Significant morbidity can result from surgical treatment of these tumors. Meningiomas, ependymomas, and other benign central nervous system tumors are also common in NF2. The lack of effective treatments for NF2 marks an unmet medical need. Experimental Design: Here, we provide recommendations from a workshop, cochaired by Drs. D. Gareth Evans and Marco Giovannini, of 36 international researchers, physicians, representatives of the biotechnology industry, and patient advocates on how to accelerate progress toward NF2 clinical trials. Results: Workshop participants reached a consensus that, based on current knowledge, the time is right to plan and implement NF2 clinical trials. Obstacles impeding NF2 clinical trials and how to address them were discussed, as well as the candidate therapeutic pipeline for NF2. Conclusions: Both phase 0 and phase II NF2 trials are near-term options for NF2 clinical trials. The number of NF2 patients in the population remains limited, and successful recruitment will require ongoing collaboration efforts between NF2 clinics. (Clin Cancer Res 2009;15(16):5032–9)
Should Clinicians Deliver Decision Aids? Further Exploration of the Statin Choice Randomized Trial Results
Jones, Lesley A., Weymiller, Audrey, Shah, Nilay D. , Bryant, Sandra C. , Christianson, Teresa J., Gafni, Amiram , Smith, Steven A., Montori, Víctor M. , Guyatt, Gordon , Montori, Victor M

Mayo Clinic

Medical Decision Making | July 15, 2009 | Volume: 29 | Issue: 4 | Pages: 468-474

10.1177/0272989x09333120 | PMID 19605885 Get It

Background. Statin Choice is a decision aid about taking statins. The optimal mode of delivering Statin Choice (or any other decision aid) in clinical practice is unknown. Methods. To investigate the effect of mode of delivery on decision aid efficacy, the authors further explored the results of a concealed 2 × 2 factorial clustered randomized trial enrolling 21 endocrinologists and 98 diabetes patients and randomizing them to 1) receive either the decision aid or pamphlet about cholesterol, and 2) have these delivered either during the office visit (by the clinician) or before the visit (by a researcher). We estimated between-group differences and their 95% confidence intervals (CI) for acceptability of information delivery (1—7), knowledge about statins and coronary risk (0—9), and decisional conflict about statin use (0—100) assessed immediately after the visit. Follow-up was 99%. Results. The relative efficacy of the decision aid v. pamphlet interacted with the mode of delivery. Compared with the pamphlet, patients whose clinicians delivered the decision aid during the office visit showed significant improvements in knowledge (difference of 1.6 of 9 questions, CI 0.3, 2.8) and nonsignificant trends toward finding the decision aid more acceptable (odds ratio 3.1, CI 0.9, 11.2) and having less decisional conflict (difference of 7 of 100 points, CI - 4, 18) than when a researcher delivered the decision aid just before the office visit. Conclusions. Delivery of decision aids by clinicians during the visit improves knowledge and shows a trend toward better acceptability and less decisional conflict.
Treatment of myelodysplastic syndrome patients with erythropoietin with or without granulocyte colony-stimulating factor: results of a prospective randomized phase 3 trial by the Eastern Cooperative Oncology Group (E1996)
Greenberg, Peter L. , Sun, Zhuoxin , Miller, Kenneth B., Bennett, John M. , Tallman, Martin S. , Dewald, Gordon W., Paietta, Elisabeth , Jagt, Richard van der , Houston, Jessie G., Thomas, Mary L., Cella, David , Rowe, Jacob M.

Mayo Clinic

Blood | June 29, 2009 | Volume: 114 | Issue: 12 | Pages: 2393-2400

10.1182/blood-2009-03-211797 | PMID 19564636 Get It

Abstract This phase 3 prospective randomized trial evaluated the efficacy and long-term safety of erythropoietin (EPO) with or without granulocyte colony-stimulating factor plus supportive care (SC; n = 53) versus SC alone (n = 57) for the treatment of anemic patients with lower-risk myelodysplastic syndromes. The response rates in the EPO versus SC alone arms were 36% versus 9.6%, respectively, at the initial treatment step, 47% in the EPO arm, including subsequent steps. Responding patients had significantly lower serum EPO levels (45% vs 5% responses for levels < 200 mU/mL vs ≥ 200 mU/mL) and improvement in multiple quality-of-life domains. With prolonged follow-up (median, 5.8 years), no differences were found in overall survival of patients in the EPO versus SC arms (median, 3.1 vs 2.6 years) or in the incidence of transformation to acute myeloid leukemia (7.5% and 10.5% patients, respectively). Increased survival was demonstrated for erythroid responders versus nonresponders (median, 5.5 vs 2.3 years). Flow cytometric analysis showed that the percentage of P-glycoprotein+ CD34+ marrow blasts was positively correlated with longer overall survival. In comparison with SC alone, patients receiving EPO with or without granulocyte colony-stimulating factor plus SC had improved erythroid responses, similar survival, and incidence of acute myeloid leukemia transformation.
A critical role for phosphatase haplodeficiency in the selective suppression of deletion 5q MDS by lenalidomide
Sheng, Wei , Chen, Xianghong , Rocha, Kathy, Epling‐Burnette, Pearlie K. , Djeu, Julie Y., Byrd, John C. , Sokol, Lubomir , Lawrence, Nick, Pireddu, Roberta , Dewald, Gordon W., Williams, Ann H., Maciejewski, Jaroslaw P. , List, Alan F. , Byrd, John C. , Liu, Qing , Sokol, Lubomir , Byrd, John C

Mayo Clinic

Proceedings of the National Academy of Sciences | May 26, 2009 | Volume: 106 | Issue: 31 | Pages: 12974-12979

10.1073/pnas.0811267106 | PMID 19470455 Get It

Lenalidomide is the first karyotype-selective therapeutic approved for the treatment of myelodysplastic syndromes (MDS) owing to high rates of erythroid and cytogenetic response in patients with chromosome 5q deletion [del(5q)]. Although haploinsufficiency for the RPS14 gene and others encoded within the common deleted region (CDR) have been implicated in the pathogenesis of the del(5q) phenotype, the molecular basis of the karyotype specificity of lenalidomide remains unexplained. We focused our analysis on possible haplodeficient enzymatic targets encoded within the CDR that play key roles in cell-cycle regulation. We show that the dual specificity phosphatases, Cdc25C and PP2Acα, which are coregulators of the G 2 -M checkpoint, are inhibited by lenalidomide. Gene expression was lower in MDS and acute myeloid leukemia (AML) specimens with del(5q) compared with those with alternate karyotypes. Lenalidomide inhibited phosphatase activity either directly (Cdc25C) or indirectly (PP2A) with corresponding retention of inhibitory phospho-tyrosine residues. Treatment of del(5q) AML cells with lenalidomide induced G 2 arrest and apoptosis, whereas there was no effect in nondel(5q) AML cells. Small interfering RNA (shRNA) suppression of Cdc25C and PP2Ac α gene expression recapitulated del(5q) susceptibility to lenalidomide with induction of G 2 arrest and apoptosis in both U937 and primary nondel(5q) MDS cells. These data establish a role for allelic haplodeficiency of the lenalidomide inhibitable Cdc25C and PP2Acα phosphatases in the selective drug sensitivity of del(5q) MDS.
Newer Antidepressants and Gabapentin for Hot Flashes: An Individual Patient Pooled Analysis
Loprinzi, Charles L. , Sloan, Jeff A. , Slack, Rebecca, Iyengar, Malini, Diekmann, Brent, Kimmick, Gretchen , Lovato, James , Gordon, Paul , Pandya, Kishan J., Guttuso, Thomas , Barton, Debra L. , Novotny, Paul J. , Stearns, Vered

Mayo Clinic

Journal of Clinical Oncology | March 31, 2009 | Volume: 27 | Issue: 17 | Pages: 2831-2837

10.1200/jco.2008.19.6253 | PMID 19332723 Get It

Purpose Nonhormonal treatment options have been investigated as treatments for hot flashes, a major clinical problem in many women. Starting in 2000, a series of 10 individual double-blind placebo-controlled studies has evaluated newer antidepressants and gabapentin for treating hot flashes. This current project was developed to conduct an individual patient pooled analysis of the data from these published clinical trials. Patients and Methods Individual patient data were collected from the various study investigators who published their study results between 2000 and 2007. Between-study heterogeneity for study characteristics and patient populations was tested via χ2 tests before a pooled analysis. The primary end point, the change in hot flash activity from baseline to week 4, for each agent was calculated via both weighted and unweighted approaches, using the size of the study as the weight. Basic summary statistics were produced for hot flash score and frequency using the following three statistics: raw change, percent reduction, and whether or not a 50% reduction was achieved. Results This study included seven trials of newer antidepressants and three trials of gabapentin. The optimal doses (defined by individual study results) of the newer antidepressants paroxetine, venlafaxine, fluoxetine, and sertraline decreased hot flash scores by 41%, 33%, 13%, and 3% to 18% compared with the corresponding placebo arms, respectively. The three gabapentin trials decreased hot flashes by 35% to 38% compared with the corresponding placebo arms. Conclusion Some newer antidepressants and gabapentin, within 4 weeks of therapy initiation, decrease hot flashes more than placebo.
Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project
Carson, Kenneth R. , Evens, Andrew M. , Richey, Elizabeth, Focosi, Daniele , Seymour, John F. , Laubach, Jacob P. , Bawn, Susie D., Gordon, Leo I. , Furman, Richard R. , Zelenetz, Andrew D. , Mamtani, Ronac , Raisch, Dennis W., Dorshimer, Gary W., Rosen, Steven T. , Muro, Kenji , Gottardi-Littell, Numa R., Talley, Robert L., Green, David , Major, Eugene O. , Bennett, Charles L. , Habermann, Thomas M. , Winter, Jane N. , Vose, Julie M. , Sartor, Oliver , Gordon, Leo I , Zelenetz, Andrew D , Evens, Andrew M , Focosi, Daniele

Mayo Clinic

Blood | March 6, 2009 | Volume: 113 | Issue: 20 | Pages: 4834-4840

10.1182/blood-2008-10-186999 | PMID 19264918 Get It

Rituximab improves outcomes for persons with lymphoproliferative disorders and is increasingly used to treat immune-mediated illnesses. Recent reports describe 2 patients with systemic lupus erythematosus and 1 with rheumatoid arthritis who developed progressive multifocal leukoencephalopathy (PML) after rituximab treatment. We reviewed PML case descriptions among patients treated with rituximab from the Food and Drug Administration, the manufacturer, physicians, and a literature review from 1997 to 2008. Overall, 52 patients with lymphoproliferative disorders, 2 patients with systemic lupus erythematosus, 1 patient with rheumatoid arthritis, 1 patient with an idiopathic autoimmune pancytopenia, and 1 patient with immune thrombocytopenia developed PML after treatment with rituximab and other agents. Other treatments included hematopoietic stem cell transplantation (7 patients), purine analogs (26 patients), or alkylating agents (39 patients). One patient with an autoimmune hemolytic anemia developed PML after treatment with corticosteroids and rituximab, and 1 patient with an autoimmune pancytopenia developed PML after treatment with corticosteroids, azathioprine, and rituximab. Median time from last rituximab dose to PML diagnosis was 5.5 months. Median time to death after PML diagnosis was 2.0 months. The case-fatality rate was 90%. Awareness is needed of the potential for PML among rituximab-treated persons.
Yttrium-90 Ibritumomab Tiuxetan Doses Calculated to Deliver up to 15 Gy to Critical Organs May Be Safely Combined With High-Dose BEAM and Autologous Transplantation in Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma
Inwards, David J. , Spies, Stewart, Wiseman, Gregory A., Patton, David R. , Erwin, William D. , Rademaker, Alfred , Weitner, Bing Bing, Williams, Stephanie , Tallman, Martin S. , Micallef, Ivana N. , Mehta, Jayesh, Evens, Andrew M. , Zimmer, Michael, Molina, Arturo , Gordon, Leo I. , Winter, Jane N. , Singhal, Seema , White, Christine A. , Gordon, Leo I , Evens, Andrew M , Patton, David R

Mayo Clinic

Journal of Clinical Oncology | March 3, 2009 | Volume: 27 | Issue: 10 | Pages: 1653-1659

10.1200/jco.2008.19.2245 | PMID 19255322 Get It

Purpose To determine the maximum-tolerated radiation-absorbed dose (RAD) to critical organs delivered by yttrium-90 (90Y) ibritumomab tiuxetan in combination with high-dose carmustine, etoposide, cytarabine, and melphalan (BEAM) chemotherapy with autologous transplantation. Patients and Methods Eligible patients had relapsed or refractory CD20+ non-Hodgkin's lymphoma (NHL). Individualized 90Y activities were based on dosimetry and were calculated to deliver cohort-defined RAD (1 to 17 Gy) to critical organs with three to six patients per cohort. The therapeutic dose of 90Y ibritumomab tiuxetan was followed by high-dose BEAM and autologous transplantation. Results Forty-four patients were treated. Thirty percent of patients had achieved less than a partial remission to their most recent therapy and would not have been eligible for autologous transplantation at most centers. The toxicity profile was similar to that associated with high-dose BEAM chemotherapy. Two dose-limiting toxicities occurred at the 17 Gy dose level, which made 15 Gy the recommended maximum-tolerated RAD. Although eight patients received at least twice the conventional dose of 0.4 mCi/kg, a weight-based strategy at 0.8 mCi/kg would have resulted in a wide range of RAD; nearly 25% of patient cases would have received 17 Gy or more, and many would have received less than 10 Gy. With a median follow-up of 33 months for all patients, the estimated 3-year progression-free and overall survivals were 43% and 60%, respectively. Conclusion Dose-escalated 90Y ibritumomab tiuxetan may be safely combined with high-dose BEAM with autologous transplantation and has the potential to be more effective than standard-dose radioimmunotherapy. Careful dosimetry is required to avoid toxicity and undertreatment.
Maintenance Rituximab After Cyclophosphamide, Vincristine, and Prednisone Prolongs Progression-Free Survival in Advanced Indolent Lymphoma: Results of the Randomized Phase III ECOG1496 Study
Höchster, Howard S. , Weller, Edie, Gascoyne, Randy D. , Gordon, Leo I. , Ryan, Theresa, Zhang, Lijun , Colocci, Natalia, Frankel, Stanley, Horning, Sandra J., Habermann, Thomas M. , Gordon, Leo I

Mayo Clinic

Journal of Clinical Oncology | March 3, 2009 | Volume: 27 | Issue: 10 | Pages: 1607-1614

10.1200/jco.2008.17.1561 | PMID 19255334 Get It

Purpose To determine if maintenance rituximab (MR) after standard chemotherapy improves progression-free survival (PFS) in advanced-stage indolent lymphoma. Patients and Methods Patients with stage III-IV indolent lymphoma with responding or stable disease after cyclophosphamide, vincristine, and prednisone (CVP) chemotherapy were stratified by initial tumor burden, residual disease after CVP (minimal or gross), and histology, and randomly assigned to observation (OBS) or MR 375 mg/m2 once per week for 4 weeks every 6 months for 2 years. PFS was the primary end point. Results Three hundred eleven (282 with follicular lymphoma) evaluable patients who received CVP were randomly assigned to OBS (n = 158) or MR (n = 153). Best response improved in 22% MR versus 7% OBS patients (P = .00006). Toxicity was minimal in both study arms. Three-year PFS after random assignment was 68% MR versus 33% OBS (hazard ratio [HR] = 0.4; P = 4.4 × 10−10 [all patients]) and 64% MR v 33% OBS (HR = 0.4; P = 9.2 × 10−8 [patients with follicular lymphoma]). There was an advantage for MR regardless of Follicular Lymphoma International Prognostic Index score, tumor burden, residual disease, or histology. In multivariate analysis of MR patients, minimal disease after CVP was a favorable prognostic factor. OS at 3 years was 92% MR versus 86% OBS (HR = 0.6; log-rank one-sided P = .05) and, among patients with follicular lymphoma, OS was 91% MR versus 86% (HR = 0.6; log-rank one-sided P = .08). A trend favoring MR was observed among patients with high tumor burden (log-rank one-sided P = .03). Conclusion The E1496 study provides the first phase III data in untreated indolent lymphoma that MR after chemotherapy significantly prolongs PFS.